Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

Initial development of EO-3021 in combination will explore two regimens for the treatment of gastric or gastroesophageal junction cancer: -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- About EO-3021 -- Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings -- -- On-track to provide update from ongoing Phase 1 clinical trial evaluating monotherapy EO-3021 ...